New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

RBC Capital analyst Gregory Renza maintained a Buy rating on aTyr Pharma (ATYR – Research Report) yesterday and set a price target of $16.00.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its ...